|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TIPIN |
Gene summary for TIPIN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TIPIN | Gene ID | 54962 |
| Gene name | TIMELESS interacting protein | |
| Gene Alias | TIPIN | |
| Cytomap | 15q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | B4DRF3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54962 | TIPIN | LZE7T | Human | Esophagus | ESCC | 6.77e-06 | 3.45e-01 | 0.0667 |
| 54962 | TIPIN | LZE6T | Human | Esophagus | ESCC | 1.10e-05 | 2.29e-01 | 0.0845 |
| 54962 | TIPIN | P1T-E | Human | Esophagus | ESCC | 1.65e-03 | 3.60e-01 | 0.0875 |
| 54962 | TIPIN | P2T-E | Human | Esophagus | ESCC | 2.82e-24 | 4.43e-01 | 0.1177 |
| 54962 | TIPIN | P4T-E | Human | Esophagus | ESCC | 1.97e-18 | 5.58e-01 | 0.1323 |
| 54962 | TIPIN | P5T-E | Human | Esophagus | ESCC | 8.84e-23 | 4.93e-01 | 0.1327 |
| 54962 | TIPIN | P8T-E | Human | Esophagus | ESCC | 7.29e-09 | 1.68e-01 | 0.0889 |
| 54962 | TIPIN | P9T-E | Human | Esophagus | ESCC | 4.71e-05 | 1.67e-01 | 0.1131 |
| 54962 | TIPIN | P10T-E | Human | Esophagus | ESCC | 1.48e-15 | 2.75e-01 | 0.116 |
| 54962 | TIPIN | P11T-E | Human | Esophagus | ESCC | 1.97e-02 | 1.56e-01 | 0.1426 |
| 54962 | TIPIN | P12T-E | Human | Esophagus | ESCC | 2.23e-11 | 2.42e-01 | 0.1122 |
| 54962 | TIPIN | P15T-E | Human | Esophagus | ESCC | 6.92e-08 | 1.81e-01 | 0.1149 |
| 54962 | TIPIN | P16T-E | Human | Esophagus | ESCC | 4.82e-20 | 3.87e-01 | 0.1153 |
| 54962 | TIPIN | P17T-E | Human | Esophagus | ESCC | 2.53e-02 | 1.85e-01 | 0.1278 |
| 54962 | TIPIN | P19T-E | Human | Esophagus | ESCC | 2.32e-02 | 4.69e-01 | 0.1662 |
| 54962 | TIPIN | P20T-E | Human | Esophagus | ESCC | 7.74e-03 | 1.31e-01 | 0.1124 |
| 54962 | TIPIN | P21T-E | Human | Esophagus | ESCC | 2.28e-10 | 2.13e-01 | 0.1617 |
| 54962 | TIPIN | P22T-E | Human | Esophagus | ESCC | 1.57e-04 | 1.27e-01 | 0.1236 |
| 54962 | TIPIN | P23T-E | Human | Esophagus | ESCC | 1.35e-09 | 2.95e-01 | 0.108 |
| 54962 | TIPIN | P24T-E | Human | Esophagus | ESCC | 5.82e-09 | 2.33e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000941112 | Oral cavity | LP | response to UV | 63/4623 | 149/18723 | 1.74e-06 | 4.05e-05 | 63 |
| GO:000626011 | Oral cavity | LP | DNA replication | 97/4623 | 260/18723 | 3.67e-06 | 7.75e-05 | 97 |
| GO:000931417 | Oral cavity | LP | response to radiation | 155/4623 | 456/18723 | 4.12e-06 | 8.49e-05 | 155 |
| GO:004578612 | Oral cavity | LP | negative regulation of cell cycle | 127/4623 | 385/18723 | 1.33e-04 | 1.53e-03 | 127 |
| GO:004593012 | Oral cavity | LP | negative regulation of mitotic cell cycle | 83/4623 | 235/18723 | 1.62e-04 | 1.82e-03 | 83 |
| GO:190198712 | Oral cavity | LP | regulation of cell cycle phase transition | 126/4623 | 390/18723 | 3.69e-04 | 3.64e-03 | 126 |
| GO:000709311 | Oral cavity | LP | mitotic cell cycle checkpoint | 48/4623 | 129/18723 | 1.03e-03 | 8.67e-03 | 48 |
| GO:004277013 | Oral cavity | LP | signal transduction in response to DNA damage | 60/4623 | 172/18723 | 1.71e-03 | 1.31e-02 | 60 |
| GO:001094811 | Oral cavity | LP | negative regulation of cell cycle process | 95/4623 | 294/18723 | 1.80e-03 | 1.37e-02 | 95 |
| GO:190198811 | Oral cavity | LP | negative regulation of cell cycle phase transition | 80/4623 | 249/18723 | 4.63e-03 | 2.94e-02 | 80 |
| GO:000007511 | Oral cavity | LP | cell cycle checkpoint | 57/4623 | 169/18723 | 5.05e-03 | 3.14e-02 | 57 |
| GO:004477311 | Oral cavity | LP | mitotic DNA damage checkpoint | 30/4623 | 81/18723 | 8.95e-03 | 4.82e-02 | 30 |
| GO:000734617 | Skin | cSCC | regulation of mitotic cell cycle | 192/4864 | 457/18723 | 3.47e-14 | 2.31e-12 | 192 |
| GO:190198714 | Skin | cSCC | regulation of cell cycle phase transition | 150/4864 | 390/18723 | 3.21e-08 | 8.61e-07 | 150 |
| GO:000626012 | Skin | cSCC | DNA replication | 106/4864 | 260/18723 | 1.18e-07 | 2.77e-06 | 106 |
| GO:000941114 | Skin | cSCC | response to UV | 68/4864 | 149/18723 | 1.62e-07 | 3.62e-06 | 68 |
| GO:000931424 | Skin | cSCC | response to radiation | 166/4864 | 456/18723 | 4.37e-07 | 8.41e-06 | 166 |
| GO:004593014 | Skin | cSCC | negative regulation of mitotic cell cycle | 93/4864 | 235/18723 | 3.14e-06 | 4.89e-05 | 93 |
| GO:004578613 | Skin | cSCC | negative regulation of cell cycle | 140/4864 | 385/18723 | 3.64e-06 | 5.50e-05 | 140 |
| GO:190198812 | Skin | cSCC | negative regulation of cell cycle phase transition | 94/4864 | 249/18723 | 2.65e-05 | 3.00e-04 | 94 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TIPIN | SNV | Missense_Mutation | c.769G>A | p.Glu257Lys | p.E257K | Q9BVW5 | protein_coding | tolerated_low_confidence(0.93) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TIPIN | SNV | Missense_Mutation | c.179T>C | p.Val60Ala | p.V60A | Q9BVW5 | protein_coding | tolerated(0.1) | benign(0.07) | TCGA-AR-A1AH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | PD | ||
| TIPIN | SNV | Missense_Mutation | c.781N>C | p.Asp261His | p.D261H | Q9BVW5 | protein_coding | tolerated_low_confidence(0.08) | benign(0.015) | TCGA-E2-A14Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| TIPIN | SNV | Missense_Mutation | c.650N>C | p.Lys217Thr | p.K217T | Q9BVW5 | protein_coding | deleterious(0) | possibly_damaging(0.573) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TIPIN | SNV | Missense_Mutation | rs76072153 | c.425G>A | p.Arg142Gln | p.R142Q | Q9BVW5 | protein_coding | tolerated(0.08) | benign(0.283) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TIPIN | SNV | Missense_Mutation | c.646N>A | p.Ala216Thr | p.A216T | Q9BVW5 | protein_coding | deleterious(0) | possibly_damaging(0.862) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TIPIN | SNV | Missense_Mutation | c.250N>A | p.Val84Ile | p.V84I | Q9BVW5 | protein_coding | tolerated(0.12) | benign(0.388) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TIPIN | SNV | Missense_Mutation | c.351N>C | p.Lys117Asn | p.K117N | Q9BVW5 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| TIPIN | SNV | Missense_Mutation | rs573461004 | c.25G>A | p.Val9Met | p.V9M | Q9BVW5 | protein_coding | tolerated(0.23) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| TIPIN | SNV | Missense_Mutation | novel | c.171G>T | p.Lys57Asn | p.K57N | Q9BVW5 | protein_coding | deleterious(0) | possibly_damaging(0.601) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |